Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies
Cells · 31.07.2026 · 15 (15) · 1383
DOI: 10.3390/cells15151383 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 31.07.2026. Verfasst von Eduardo Bravo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors, Drug Resistance, Neoplasm. Die Arbeit nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Florida state Department of Health, National Cancer Institute.
Abstract (Originalsprache)
Kinases are highly explored drug targets due to their central role in cell growth, differentiation, and cell death, as well as their relationship to cancer initiation and progression. However, with more than 500 kinases in the human kinome and significant structural similarities among them, kinases present a major selectivity challenge. Bruton’s tyrosine kinase (BTK), a highly studied kinase, plays an important role in the B-cell receptor pathway. Overexpression of BTK in B cells has been linked to the development of B-cell lymphomas, like chronic lymphocytic leukemia (CLL), as well as certain autoimmune diseases. For this reason, BTK is an attractive therapeutic target. In this review, we will provide a summary of the design of irreversible inhibitors, reversible inhibitors, and Proteolysis-targeting chimera (PROTAC) degraders targeting BTK. We will include crystal structures of compounds bound to BTKWT and provide a review of how the design of these inhibitors and PROTACs leads to a more selective inhibition and degradation of BTK. With the emergence of identified BTK resistance mutations, alternative strategies beyond established BTK inhibitors are fundamental for designing more selective inhibitors and degraders that can overcome resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
ORCID-Profile: Eduardo Bravo, Claudia Cabrera Pastrana, Erica N Lamkin, Justin Taylor
Förderung
- NCI NIH HHS
- Florida state Department of Health
- National Cancer Institute
Zitieren
APA
Bravo, E., Pastrana, C. C., Lamkin, E. N., Ciurko, K., & Taylor, J. (2026). Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies. Cells, 15(15), 1383. https://doi.org/10.3390/cells15151383
Vancouver
Bravo E, Pastrana CC, Lamkin EN, Ciurko K, Taylor J. Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies. Cells. 2026;15(15):1383. doi:10.3390/cells15151383
BibTeX
@article{Bravo2026,
author = {Bravo, Eduardo and Pastrana, Claudia Cabrera and Lamkin, Erica N and Ciurko, Katarzyna and Taylor, Justin},
title = {Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies},
journal = {Cells},
year = {2026},
volume = {15},
number = {15},
pages = {1383},
doi = {10.3390/cells15151383}
}
EUVIMED